Eagle Pharmaceuticals, Inc.
6 clinical trials · Sponsor
◉ Watch Eagle Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia (NCT05776004) | Eagle Pharmaceuticals, Inc. | 2023-07-22 |
| Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS (NCT03600376) | Eagle Pharmaceuticals, Inc. | 2018-08-19 |
| Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration (NCT03324061) | Eagle Pharmaceuticals, Inc. | 2017-11-30 |
| Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) (NCT03189433) | Eagle Pharmaceuticals, Inc. | 2017-08-12 |
| Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) (NCT02513095) | Eagle Pharmaceuticals, Inc. | 2015-09-01 |
| A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients (NCT02162888) | Eagle Pharmaceuticals, Inc. | 2013-11-01 |
Track Eagle Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.